Kirk Nielsen is a Managing Director at Versant, where he leads the firm's med tech practice. Kirk has led or co-led investments in BioTie (sale), Cameron Health (sale), CardiAQ (sale), Lutonix (sale), NeuWave Medical (sale), Sequent Medical (sale), Zyga Technology (sale), Ceterix Orthopedics, Inari Medical, Metavention, Monteris Medical, Nuvaira, Respicardia, and Veran Medical. Based in Minneapolis, he also leads the firm’s activities in the Midwest.
Kirk joined Versant in 2006 from Medtronic, where he worked in sales & marketing in the company’s Cardiac Rhythm Management division. Previously, he spent time at Fluidigm (a Versant portfolio company) and he also served as a consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Kirk earned his MBA from Harvard University. Prior to his business career, Kirk was a professional hockey player.